Vimarsana
Biggest News Aggregation in the World

Induced Toxicity Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Induced Toxicity Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Induced Toxicity Programs Today - Breaking & Trending Today

Galera Therapeutics : Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with decades of experience successfully launching and commercializing new oncology products - Form 8-K - Vimarsana News

Galera Therapeutics : Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with decades of experience successfully launching and commercializing new oncology products - Form 8-K

Published: May 11, 2023

Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives... | May 11, 2023

Source: marketscreener.com
Related Topics:
United StatesSan AntonioChristopher DegnanMel SorensenCarryn AndersonLorraine WalkerMark BachledaElizabeth CullenWilliam WindhamZara LockshinGalera Therapeutics IncExchange CommissionCompany ViceOncology Nursing SocietyEuropean Congress On HeadUniversity Of IowaDrug AdministrationAmerican Society Of Clinical OncologySolebury Strategic CommunicationsUniversity Of Iowa HospitalsPriority ReviewInduced Toxicity ProgramsOral MucositisNew Drug ApplicationPrescription Drug User Fee Act
Galera Reports Third Quarter 2022 Financial Results and - Vimarsana News

Galera Reports Third Quarter 2022 Financial Results and

Published: November 9, 2022

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation...

Source: globenewswire.com
Related Topics:
United StatesMel SorensenEugenep KennedyJont HolmlundExchange CommissionAmerican Society For Radiation OncologyHepatobiliary Surgery At Thomas Jefferson UniversityDrug AdministrationGalera Therapeutics IncRadiation OncologyAnnual MeetingNew Drug ApplicationInduced Toxicity ProgramsOral MucositisCancer ProgramsAdvanced Pancreatic CancerSmall Cell Lung CancerCorporate UpdatesChief MedicalJohns Hopkins TrainedHepatobiliary SurgeryThomas Jefferson UniversityPrivate Securities Litigation Reform ActBreakthrough Therapy DesignationFast Track Designation
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates - Vimarsana News

Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Published: May 16, 2022

16.05.2022 - Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral ...

Source: wallstreet-online.de
Related Topics:
United StatesChristopher DegnanMel SorensenZara LockshinWilliam WindhamExchange CommissionAmerican Society Of Clinical OncologyDrug AdministrationGalera Therapeutics IncInduced Toxicity ProgramsOral MucositisNew Drug ApplicationClinical OncologyCancer ProgramsAdvanced Pancreatic CancerSmall Cell Lung CancerPrivate Securities Litigation Reform ActBreakthrough Therapy DesignationFast Track DesignationAnnual ReportMonths Ended March